MiR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Lei, Ye ^a   Li, Bin ^b   Tong, Shiyu ^a   Qi, Lin ^a   Hu, Xiheng ^a   Cui, Yunbo ^c   Li, Zengbo ^a   He, Wei ^a   Zu, Xiongbing ^a   Wang, Zhi ^a   Chen, Minfeng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; LENTIVIRUS VECTOR; LUCIFERASE; MICRORNA 101; PLASMID VECTOR; VASCULOTROPIN C; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; MICRORNA; MIRN101 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; BLADDER CANCER CELL LINE; CANCER INHIBITION; CELL ASSAY; CELL INVASION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; EXPRESSION VECTOR; FILTERS AND MEMBRANES; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC50; LUCIFERASE ASSAY; POSTTRANSCRIPTIONAL GENE SILENCING; PROTEIN EXPRESSION; PROTEIN RNA BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA INTERFERENCE; RNA PROCESSING; VALIDATION STUDY; WESTERN BLOTTING; WOUND HEALING; BLADDER TUMOR; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

LENTIVIRUS;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CISPLATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; LUCIFERASES; MICRORNAS; MICROSCOPY, FLUORESCENCE; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM INVASIVENESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84922645065     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117809     Document Type: Article

References (36)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917. doi: 10.1002/ijc.25516 PMID: 21351269
2. Herr HW (2001) Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19: 89-93. PMID: 11134199
3. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, et al. (2010) Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 11: 861-870. doi: 10.1016/S1470-2045(10)70086-3 PMID: 20537950
4. Rosenberg JE, Carroll PR, Small EJ (2005) Update on chemotherapy for advanced bladder cancer. J Urol 174: 14-20. PMID: 15947569
5. Leissner J, Koeppen C, Wolf HK (2003) Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J Urol 169: 955-960. PMID: 12576821
6. Frank I, Cheville JC, Blute ML, Lohse CM, Nehra A, et al. (2003) Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome. Cancer 97: 2425-2431. PMID: 12733141
7. Tanji N, Ozawa A, Miura N, Yanagihara Y, Sasaki T, et al. (2010) Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas. Int J Clin Onco 15: 369-375. doi: 10.1007/s10147-010-0069-2 PMID: 20340038
8. Walz J, Shariat SF, Suardi N, Perrotte P, Lotan Y, et al. (2008) Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. BJU Int 101: 1356-1361. doi: 10.1111/j.1464-410X.2008.07524.x PMID: 18454792
9. Canter D, Guzzo T, Resnick M, Magerfleisch L, Sonnad S, et al. (2008) The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis. BJU Int 102: 952-957. doi: 10.1111/j.1464-410X.2008.07732.x PMID: 18485042
10. Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, et al. (2009) Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 73: 147-152. doi: 10.1016/j.urology.2008.07.035 PMID: 18848348
11. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233. doi: 10.1016/j.cell.2009.01.002 PMID: 19167326
12. Croce CM, Calin GA (2005) miRNAs, cancer, and stem cell division. Cell 122: 6-7. PMID: 16009126
13. Lujambio A, Lowe SW (2012) The microcosmos of cancer. Nature 482: 347-355. doi: 10.1038/ nature10888 PMID: 22337054
14. Nordentoft I, Birkenkamp-Demtroder K, Agerbaek M, Theodorescu D, Ostenfeld MS, et al. (2012) miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics 5: 40. doi: 10.1186/1755-8794-5-40 PMID: 22954303
15. Friedman JM, Liang G, Liu CC, Wolff EM, Tsai YC, et al. (2009) The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 69: 2623-2629. doi: 10.1158/0008-5472.CAN-08-3114 PMID: 19258506
16. Hao Y, Gu X, Zhao Y, Greene S, Sha W, et al. (2011) Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res 4: 1073-1083. doi: 10.1158/1940-6207.CAPR-10-0333 PMID: 21430074
17. Guo F, Cogdell D, Hu L, Yang D, Sood AK, et al. (2014) MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol Rep 31: 2021-2028. doi: 10.3892/or.2014.3106 PMID: 24677166
18. Schee K, Boye K, Abrahamsen TW, Fodstad O, Flatmark K (2012) Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 12: 505. doi: 10.1186/1471-2407-12-505 PMID: 23121918
19. Su H, Yang JR, Xu T, Huang J, Xu L, et al. (2009) MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 69: 1135-1142. doi: 10.1158/0008-5472.CAN-08-2886 PMID: 19155302
20. Wang HJ, Ruan HJ, He XJ, Ma YY, Jiang XT, et al. (2010) MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer 46: 2295-2303. PMID: 20712078
21. Luo L, Zhang T, Liu H, Lv T, Yuan D, et al. (2012)MiR-101 andMcl-1 in non-small-cell lung cancer: expression profile and clinical significance. MedOncol 29: 1681-1686. doi: 10.1007/s12032-011-0085-8 PMID: 21993632
22. Wang R,Wang HB, Hao CJ, Cui Y, Han XC, et al. (2012)MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1. PloS One 7: e46173. doi: 10.1371/journal.pone.0046173 PMID: 23071542
23. Lin X, Guan H, Li H, Liu L, Liu J, et al. (2014) miR-101 inhibits cell proliferation by targeting Rac1 in papillary thyroid carcinoma. Biomed Rep 2: 122-126. PMID: 24649082
24. Luo C, Merz PR, Chen Y, Dickes E, Pscherer A, et al. (2013) MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett 341: 240-247. doi: 10.1016/j.canlet.2013. 08.021 PMID: 23962556
25. Tammela T, Alitalo K (2010) Lymphangiogenesis: Molecular mechanisms and future promise. Cell 140: 460-476. doi: 10.1016/j.cell.2010.01.045 PMID: 20178740
26. Leppanen VM, Tvorogov D, Kisko K, Prota AE, Jeltsch M, et al. (2013) Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proc Natl Acad Sci U S A 110: 12960-12965. doi: 10.1073/pnas.1301415110 PMID: 23878260
27. Trojan L, Rensch F, Voss M, Grobholz R, Weiss C, et al. (2006) The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer. BJU Int 98: 903-906. PMID: 16978291
28. Su JL, Yang PC, Shih JY, Yang CY, Wei LH, et al. (2006) The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 9: 209-223. PMID: 16530705
29. Jun Cho H, Kim IK, Park SM, Eun Baek K, Nam IK, et al. (2014) VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance. Int J Cancer 135: 1553-1563. doi: 10.1002/ijc. 28801 PMID: 24585459
30. Yafi FA, KassoufW(2009) Role of lymphadenectomy for invasive bladder cancer. Can Urol Assoc J 3: S206-210. PMID: 20019986
31. Ratert N,Meyer HA, Jung M,Mollenkopf HJ,Wagner I, et al. (2012) ReferencemiRNAs for miRNAome analysis of urothelial carcinomas. PloS One 7: e39309. doi: 10.1371/journal.pone.0039309 PMID: 22745731
32. Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC, et al. (2011) FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol cell 43: 285-298. doi: 10.1016/j.molcel.2011.06.020 PMID: 21777817
33. Hu Z, Lin Y, Chen H, Mao Y, Wu J, et al. (2013) MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. Biochem Biophys Res Commun 435: 82-87. doi: 10.1016/j.bbrc.2013.04.042 PMID: 23618864
34. Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, et al. (1998) Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A 95: 14389-14394. PMID: 9826710
35. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, et al. (1996) A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15: 290-298. PMID: 8617204
36. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, et al. (1997) Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276: 1423-1425. PMID: 9162011